LYNCH REGENERATIVE MEDICINE, LLC – Trademark Portfolio
Entity Type: 16
LYNCH REGENERATIVE MEDICINE, LLC holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 2 are pending. Notable registered marks include ABSOLVE and REGRANEX. The owner is based in FRANKLIN, TN.
393 NICHOL MILL LANE
SUITE 150
FRANKLIN, TN 37067
Showing of trademarks Trademarks
Trademark Classifications
LYNCH REGENERATIVE MEDICINE, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does LYNCH REGENERATIVE MEDICINE, LLC have?
LYNCH REGENERATIVE MEDICINE, LLC has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 pending.
What trademark classes does LYNCH REGENERATIVE MEDICINE, LLC file in?
LYNCH REGENERATIVE MEDICINE, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are LYNCH REGENERATIVE MEDICINE, LLC's most well-known trademarks?
LYNCH REGENERATIVE MEDICINE, LLC's registered trademark portfolio includes well-known marks such as ABSOLVE and REGRANEX. These are among 3 currently registered trademarks in the portfolio.
What is LYNCH REGENERATIVE MEDICINE, LLC's trademark registration success rate?
LYNCH REGENERATIVE MEDICINE, LLC has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 2 applications are pending review.